Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma.

Bei-Lei LiuXiaona FangDora Lai-Wan KwongYu ZhangKrista VerhoeftLanqi GongBaifeng ZhangJie ChenQianqian YuJie LuoYing TangTuxiong HuangFei LingLi FuQian YanXin-Yuan Guan

Published in: Journal of experimental & clinical cancer research : CR (2022)

We demonstrated that TROY is an HCC CSC marker and plays an important role in HCC stemness regulation. Targeting TROY-positive CSCs with PI3K inhibitor wortmannin combined with chemo- or targeted drugs might be a novel therapeutic strategy for HCC patients.

Keyphrases

cancer therapy
end stage renal disease
stem cells
epithelial mesenchymal transition
chronic kidney disease
newly diagnosed
ejection fraction
cancer stem cells
signaling pathway
drug delivery
peritoneal dialysis
photodynamic therapy
prognostic factors
cell proliferation
locally advanced
patient reported